Inhibitors of protein tyrosine phosphatase

Compounds of the formula VI:

• wherein A is —C(O)—;
• wherein G7 is
• a) —R28;
• wherein G8 is
• c) CH2OH;
• wherein R27 is
• a) —OSO3H,
• b) —OCH(CO2R31)2,
• c) —OCH2(CO2R31),
• d) —OCH(CO2R31)CH2CO2R31,
• e) —OC(CO2R31)═CHCO2R31,
• f) —CH2CH(CO2R31)2,
• g) —CH═C(CO2R31)2,
• h) —OCH2CONHOH,
• i) —N(CH2CO2R31)2, or
• j) —OCHF(CO2R31);
• wherein R28 is
• e) —CH(R33)NHXR32, or
• f)
• wherein R31 is
• a) —H,
• b) —C1-C10 alkyl, or
• c) —C1-C5 alkyl-phenyl;
• wherein R32 is
• a) —C1-C10 alkyl,
• b) —C0-C6 alkyl-G9,
• c) —C1-C6 alkyl CONH2,
• d) —C1-C6 alkyl NHCO2R31,
• e) —C1-C6 alkyl-OR31,
• f) —C1-C6 alkyl-NHSO2Me,
• g) —C1-C6 alkyl-O—G9,
• h) —C1-C6 alkyl-S—G9, or
• i) —C1-C6 alkyl-CO2R31;
• wherein R33 is
• a) —H,
• b) —C1-C6 alkyl-G9,
• c) —C1-C6 alkyl-CO2R31,
• d) —C1-C6 alkyl CONH2,
• e) —C1-C6 alkyl NHCO2R31,
• f) —C1-C10 alkyl,
• g) —C1-C10 cycloalkyl,
• h) —C1-C6 alkyl-SR31, or
• i) —C1-C6 alkyl-S(═O)R31;
• wherein R34 is
• a) C0-C6 alkyl-G9,
• b) CH(R33)CO2R31,
• c) CH(R33)CH2CO2R31, or
• d) CH(R33)CONHCH2CO2R31;
• wherein G9 is
• a) phenyl substituted by zero (0) to four (4) R35,
• b) naphthyl substituted by zero (0) to three (3) R35, or
• c) het1 substituted by zero (0) to three (3) R35;
• wherein het1 is a 5- or 6-membered saturated or unsaturated ring containing from one (1) to four (4) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
• and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, C3-C8 cycloalkyl, or another heterocycle;
• and optionally, the nitrogen and sulfur heteroatoms may be in oxidized form;
• wherein R35 may be any of the following:
• a) C1-C8 alkyl substituted by zero (0) to three (3) halo,
• b) C2-C8 alkenyl,
• c) OH,
• d) O—C1-C5 alkyl,
• e) O—C0-C5 alkyl-phenyl,
• f) —(CH2)n—O—C1-C5 alkyl substituted by zero (0) to three (3) hydroxy,
• g) —(CH2)n—O—C2-C7 alkenyl substituted by zero (0) to three (3) hydroxy,
• h) halo,
• i) NH2,
• j) amino-C1-C5 alkyl,
• k) mono- or di-C1-C5 alkylamino,
• l) —C(O)—C1-C5 alkyl,
• m) —CHO,
• n) —C(O)—C0-C5 alkyl-phenyl,
• o) —COOR31,
• p) —CON(R31)2,
• q) —C3-C7 cycloalkyl,
• r) —NO2,
• s) —CN,
• t) —SO3H,
• u) —SO2N(R31)2,
• v) —O[(CH2)2—O]n—CH3,
• w) —[CH2—O]n—C1-C3 alkyl,
• x) —NR31(CO)—NR3,
• y) —CF3,
• z) —NR31(CO)C1-C5 alkyl,
• a1) —N(R31)—SO2—R31,
• b1) —O—C(O)—R31,
• c1) —S(O)—R31,
• d1) —SR31,
• e1) —SO2—R31,
• f1) phenyl, or
• g1) oxo;
• wherein R36 is
• a) —H,
• b) —CO2R31,
• c) —CONHOH,
• d) het2 substituted by zero to three R35, where in het2 is a 5- or 6-membered saturated or unsaturated ring containing from one (1) to four (4) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur,
• e) F,
• f) OCH2CO2R31, or
• g)
• wherein R37 is
• a) H;
• wherein X is —CO— or —SO2— or —CO2—;
• wherein n is zero, one, two or three;
• or a pharmaceutically acceptable salt thereof;
• provided that when R36 is H, R27 is other than —OCH2(CO2R31).